Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Martelli

Showing results (511-520 of 549) with videos related to

Pageof 55
Sort By:
Leukemia|April 16, 2011
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapyL S Steelman, R A Franklin, S L Abrams, et al.
Cell Cycle (Georgetown, Tex.)|November 20, 2012
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineWilliam H Chappell, Stephen L Abrams, Richard A Franklin, et al.
Advances in Biological Regulation|July 8, 2018
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticalsStephen L Abrams, Kvin Lertpiriyapong, Li V Yang, et al.
Journal of Cellular Physiology|February 9, 2011
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathwaysJames A McCubrey, Linda S Steelman, C Ruth Kempf, et al.
Cells|April 30, 2021
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and NutraceuticalsStephen L Abrams, Shaw M Akula, Akshaya K Meher, et al.
Leukemia|August 26, 2006
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trialM Ladetto, S Vallet, F Benedetti, et al.
International Journal of Cancer|May 25, 2005
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interactionElisabetta Contardi, Giulio L Palmisano, Pier Luigi Tazzari, et al.
Frontiers in Oncology|March 27, 2026
Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Frontiers in Oncology|March 4, 2026
Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Biochimica Et Biophysica Acta|November 28, 2006
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Pageof 55

Showing results (511-520 of 549) with videos related to

Sort By:
Pageof 55
Leukemia|April 16, 2011
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapyL S Steelman, R A Franklin, S L Abrams, et al.
Cell Cycle (Georgetown, Tex.)|November 20, 2012
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineWilliam H Chappell, Stephen L Abrams, Richard A Franklin, et al.
Advances in Biological Regulation|July 8, 2018
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticalsStephen L Abrams, Kvin Lertpiriyapong, Li V Yang, et al.
Journal of Cellular Physiology|February 9, 2011
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathwaysJames A McCubrey, Linda S Steelman, C Ruth Kempf, et al.
Cells|April 30, 2021
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and NutraceuticalsStephen L Abrams, Shaw M Akula, Akshaya K Meher, et al.
Leukemia|August 26, 2006
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trialM Ladetto, S Vallet, F Benedetti, et al.
International Journal of Cancer|May 25, 2005
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interactionElisabetta Contardi, Giulio L Palmisano, Pier Luigi Tazzari, et al.
Frontiers in Oncology|March 27, 2026
Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Frontiers in Oncology|March 4, 2026
Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Biochimica Et Biophysica Acta|November 28, 2006
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Pageof 55